The Career Life of Scott Rocklage

Scott Rocklage is one of the most celebrated researchers in the field of health care management. He has been in the industry for over 3 decades and has no intentions of retiring anytime soon. He is known for 5AM Ventures, which is a leading biotechnology company located in Palm Beach.

 

Scott Rocklage joined 5AM Ventures in the year 2003. He had known the founders, Andy Schwab, John Diekman and Carin Mueller, for a number of years. Within the first year of working with the company, he was already leading the company. He had quickly been promoted to become the managing partner.

 

With 5AM Ventures, Rocklage is revolutionizing the health care industry. This biotechnology company is interested in changing the nature of the health industry. Basically, the work by proving financial aid to companies that are doing research in this field. They also provide consultation services for the same. Rocklage has been responsible for partnering the company with research firms such as Chelsea Therapeutics and Alexa. His good work landed him a position at the board of directors, in the year 2013.

 

Prior to joining the 5AM team, Rocklage worked for Cubist Pharmaceuticals Inc. He had been with the company since the year 1994 to the year 2003. Rocklage was the Chief Executiev Officer of the Company. He also served on the board of directors as its chairperson. That is from the year 2000.

 

Scott Rocklage also worked with Nycomed Salutar. He worked with this diagnostic imaging firm for a number of years. He started out as a regular employee at the research company and quickly raised the ranks. In the year 1986, he was appointed to the position of Chief Executive Officer, a position that he held till the year 1989.

 

Other than working as a managing partner at 5Am Ventures, Rocklage holds a number of positions with other firms within the industry. He serves on the board of directors of Rennovia Inc. and Kinestral Technologies, where he is the chairman. He also serves as a member of the board for Achaogen Inc. and Epirus Biopharmaceuticals.

Leave a Reply

Your email address will not be published. Required fields are marked *